
Daniel Janney
QuietNamed in filings at Alta PartnersOn the current fund
- Board seats filed
- 9

Named in filings at Alta PartnersOn the current fund
all filings on record
last 24 months
from a verified or cited source
| Progentos Therapeutics | Biotech & pharma | May 2024 | None on file |
| SUTRO BIOPHARMA | Biotech & pharma | May 2018 | Samsara Biocapital, SV Life Sciences |
| Allakos | Biotech & pharma | November 2017 | NEA |
| Krystal Biotech | Biotech & pharma | August 2017 | None on file |
| PROLACTA BIOSCIENCE | Biotech & pharma | November 2016 | None on file |
| Evolve Biosystems | Biotech & pharma | July 2015 | Energy Impact Partners |
| VIVEVE MEDICAL | Medical devices | September 2014 | None on file |
| Esperion Therapeutics | Biotech & pharma | June 2014 | Longitude Capital |
| Virobay | Biotech & pharma | May 2010 | None on file |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The category is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Categories of companies where filings name Daniel Janney on the board, based on 9 filed seats with a verified or cited source.